The BRAF inhibitor vemurafenib activates mitochondrial metabolism and inhibits hyperpolarized pyruvate-lactate exchange in BRAF mutant human melanoma cells.
Authors
Delgado-Goni, TFalck Miniotis, M
Wantuch, S
Parkes, Harold G
Marais, Richard
Workman, P
Leach, M
Beloueche-Babari, M
Affiliation
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer ResearchCancer Research UKIssue Date
2016-10-07
Metadata
Show full item recordAbstract
Understanding the impact of BRAF signaling inhibition in human melanoma on key disease mechanisms is important for developing biomarkers of therapeutic response and combination strategies to improve long term disease control. This work investigates the downstream metabolic consequences of BRAF inhibition with vemurafenib, the molecular and biochemical processes that underpin them, their significance for antineoplastic activity and potential as non-invasive imaging response biomarkers.(1)H NMR spectroscopy showed that vemurafenib decreases the glycolytic activity of BRAF mutant (WM266.4 and SKMEL28) but not BRAFWT (CHL-1 and D04) human melanoma cells. In WM266.4 cells, this was associated with increased acetate, glycine and myo-inositol levels and decreased fatty acyl signals, while the bioenergetic status was maintained. (13)C NMR metabolic flux analysis of treated WM266.4 cells revealed inhibition of de novo lactate synthesis and glucose utilization, associated with increased oxidative and anaplerotic pyruvate carboxylase mitochondrial metabolism and decreased lipid synthesis. This metabolic shift was associated with depletion of HKII, acyl-CoA dehydrogenase 9, 3-phosphoglycerate dehydrogenase and monocarboxylate transporter (MCT) 1 and 4 in BRAF mutant but not BRAFWT cells and, interestingly, decreased BRAF mutant cell dependency on glucose and glutamine for growth. Further, the reduction in MCT1 expression observed led to inhibition of hyperpolarized 13C-pyruvate-lactate exchange, a parameter that is translatable to in vivo imaging studies, in live WM266.4 cells. In conclusion, our data provide new insights into the molecular and metabolic consequences of BRAF inhibition in BRAF-driven human melanoma cells that may have potential for combinatorial therapeutic targeting as well as non-invasive imaging of response.Citation
The BRAF inhibitor vemurafenib activates mitochondrial metabolism and inhibits hyperpolarized pyruvate-lactate exchange in BRAF mutant human melanoma cells. 2016 Mol. Cancer Ther.Journal
Molecular Cancer TherapeuticsDOI
10.1158/1535-7163.MCT-16-0068PubMed ID
27765851Type
ArticleLanguage
enISSN
1538-8514ae974a485f413a2113503eed53cd6c53
10.1158/1535-7163.MCT-16-0068
Scopus Count
Collections
Related articles
- Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
- Authors: Delgado-Goñi T, Galobart TC, Wantuch S, Normantaite D, Leach MO, Whittaker SR, Beloueche-Babari M
- Issue date: 2020 Jan
- Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in BRAF(V600E) Papillary Thyroid Carcinoma.
- Authors: Valvo V, Iesato A, Kavanagh TR, Priolo C, Zsengeller Z, Pontecorvi A, Stillman IE, Burke SD, Liu X, Nucera C
- Issue date: 2021 Sep
- The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.
- Authors: Peh J, Fan TM, Wycislo KL, Roth HS, Hergenrother PJ
- Issue date: 2016 Aug
- Metabolic imaging using hyperpolarized (13) C-pyruvate to assess sensitivity to the B-Raf inhibitor vemurafenib in melanoma cells and xenografts.
- Authors: Acciardo S, Mignion L, Lacomblez E, Schoonjans C, Joudiou N, Gourgue F, Bouzin C, Baurain JF, Gallez B, Jordan BF
- Issue date: 2020 Jan
- Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition.
- Authors: Abildgaard C, Dahl C, Basse AL, Ma T, Guldberg P
- Issue date: 2014 Sep 3